Sight OLO®TechnologyEvidenceAbout UsCareersKnowledge CenterPress

Clinical Evidence

Discover our latest testimonials and publications
Doctor checking child's heartbeat
Clinton Family Care - Mississippi, USADr. David B. Wheat MDPhysician, POL
American flag

"The number one reason to deploy OLO was to reduce overhead cost. With OLO, we do not need to manage all the reagents, diluents and cleaning supplies, in addition to the quality control materials, which can be quite a lot of administrative work for a lean staff like ours. The real value is customer service, and Sight is just exceptional. It’s so far beyond anything I’ve seen in the industry."

Boston Children's Hospital - Boston, USDr. Carlo BrugnaraDirector, Hematology Lab
American Flag

"OLO’s performance is comparable to analyzers that are 50 times bigger and much more complicated to operate. The ability to take that much analytical power outside of the central lab and bring it to any setting where you can perform a CBC analysis in minutes has huge implications for hospital wards, such as oncology clinics, emergency rooms and beyond."

Nicklaus Children's Hospital - Miami, USDr. Steven MelnickChief, Department of Pathology
American Flag

"To treat children in our urgent care centers, a CBC is essential. OLO represents a major innovation in our laboratories’ CBC analysis: low blood volume (finger-prick) sampling for a five-part differential with flagging. It’s a truly welcome development. At current volumes, we believe OLO could substantially reduce our costs."

Oxford University Hospitals NHS Foundation Trust - Oxford, UKIan SmithScreening Laboratory and Point of Care Testing Manager
United Kingdom Flag

"One of the main benefits of Sight OLO is that it’s easy to maintain. Because it has a cartridge-based system that stores all the reagents within a single cartridge, it doesn’t require buffer packs or calibrations that may require further maintenance. Sight OLO can both improve and expedite the treatment decision process for our healthcare providers."

Oldham Integrated Care Centre - Manchester, UKHelen LightResearch Nurse, Pennine MSK Partnership
British Flag

"OLO has user friendly prompts for each step of the preparation so it’s impossible to go wrong. It even completes its own QC checks. It can be invaluable to have the patient's FBC within the consultation."

Sheba Tel Hashomer Medical Center - Tel Aviv, ISRDr. Ram DoolmanDirector, Laboratories Division & Automated Mega-Laboratory
Israeli Flag

"The Sight OLO successfully completed a comprehensive evaluation study at the Sheba Tel Hashomer Medical Center. The evaluation compared OLO’s performances to a state-of-the-art analyzer and experienced microscopists, across a wide clinical range. OLO’s excellent performance exceeded predefined acceptance criteria in all aspects. Following the evaluation, we have started a research collaboration with the aim to explore the diagnostic potential of visual signatures in the blood images among different patient populations, including those with COVID-19."

Publications

Published:
July 15, 2021
American Journal of Hematology
An Artificial Intelligence-Assisted Diagnostic Platform for Rapid Near-Patient Hematology

Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at near-patient care. Sight OLO® is a novel hematological platform which provides a 19 parameter, five-part differential CBC, and is designed to address the limitations in current hematology analyzers using recent advances in artificial intelligence (AI) and computer vision.

Published:
May 25, 2022
Journal of Laboratory Medicine cover image
Point-of-care Haematological Monitoring During Treatment with Clozapine

Atkins, M., McGuire, P., Balgobin, B., Williams, S., Ceesay, F., Desouza, N., Patel, P. & Taylor, D. (2022). Point-of-care haematological monitoring during treatment with clozapine.LaboratoriumsMedizin,().https://doi.org/10.1515/labmed-2021-0181

Regulatory Submissions

American flag
November 1st, 2019FDA 510(k) Cleared for Use in Moderately Complex Labs

We'd love to hear from you.